Material Detail

Healthcare Finance | MITx on edX

Healthcare Finance | MITx on edX

Funding for fundamental science and early-stage translational medicine is becoming scarcer, and at the worst possible time—when we now have the scientific and engineering expertise to make major breakthroughs in our understanding of the molecular basis of many deadly diseases and how to treat or prevent them. The dearth of funding for translational medicine in the so-called “Valley of Death” can be attributed to several factors, but a common...

Show More

Quality

  • User Rating
  • Comments
  • Learning Exercises
  • Bookmark Collections (3) Bookmark Collections
  • Course ePortfolios
  • Accessibility Info

More about this material

Comments

Log in to participate in the discussions or sign up if you are not already a MERLOT member.